Genmab — November 2024

[E_L]

do they give a source?

[Solsen]

@peter12 Tak og spændende. Nyt område Genmab tager fat i.

[Sukkeralf]

mon det er sammen med A
rgenX

[peter12]

As of now, GEN1078 has entered clinical trials to evaluate its safety, tolerability, and efficacy. Early-stage trials have shown promising results, with the drug being well-tolerated and demonstrating a reduction in markers of inflammation. Genmab and its development partner, Janssen Pharmaceuticals, are likely focusing on optimizing dosing, expanding clinical trials to different patient populations, and assessing its long-term effects and potential for combination with other treatments.

[peter12]

No source

[peter12]

Man skal nok tage det med lidt salt...

[Sukkeralf]

Lyder ikke sandsynligt det er sammen med Janssen

[E_L]

yea, i would be a bit carefull, i saw another AI said it is a CD3xCD38 duobody... doubt
that too...

[ProinvestorNEWS]

Genmabs guldæg sørger for fortsat vækst og oppræcisering https://proinvestor.com/investornyt/1238683/genmabs-guldaeg-sorger-for-fortsat-vaekst-og-oppraecisering

[Solsen]

Ingen data på erzo før JNJ har truffet en beslutning i Q125

[Bulder]

Shit

[Solsen]

Vel meget godt. Ellers ville der blive megen gætterier.

[Solsen]

Datapakke til JNJ ultimo december. Herefter 60 dage til beslutning.

[Bulder]

Når de ikke vil afsløre topline data før jnj har besluttet sig, bliver der da netop gætterier.

[Solsen]

Man kan tænke meget på den beslutning. Ved ikke hvad man skal lægge i det.

[Bulder]

Så 4 mdr mere ude i ørkenen. Vi ender som ørkenens sønner.

[Solsen]

De har det da sjovt

[w]

Var tidligere udmelding at data blev præsenteret først.

[E_L]

Jan said at conference : Next year we will see the detailed clinical data. Maybe we'll give you some top-line data this year.
We have not decided that

[E_L]

key word being 'maybe'